(DTIL) – Business Wire
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
-
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
-
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
-
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
-
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
-
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
-
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
-
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
-
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
-
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
-
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
-
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
-
Precision BioSciences to Effect a Reverse Stock Split
-
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
-
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
-
iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506
-
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
-
Precision BioSciences to Present at Hep-DART 2023
-
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
-
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
-
Precision BioSciences to Present at Upcoming Sidoti Conference
-
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
-
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Precision BioSciences to Report Third Quarter Results on November 7, 2023
-
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
-
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
-
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
-
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
-
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
-
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
-
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
-
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
-
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Precision BioSciences to Report Second Quarter Results on August 4, 2023
-
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
-
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
-
Precision BioSciences to Present at Upcoming June Investor Conferences
-
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
-
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
-
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
-
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
-
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meet
-
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
-
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
-
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meetin
-
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meetin
-
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
Back to DTIL Stock Lookup
